The orphan designation does not mean that much to me. Yes its good PR, yes it turns some heads, yes there is some money involved. What I do find VERY interesting is this fact: According to FDA rules I think a company may apply for orphan drug designation at any time BEFORE
new drug application (NDA), and the 7 years exclusivity applies from that date. That being the case (if it is), I find it EXTREMELY interesting that xoma waited UNTIL just recently to apply for orphan status. Kind of like really late in the game to maximize the 7 year exclusivity rule, but PRIOR to sept. HINT HINT.
IMO they are being VERY smart about this.
Also, I vote you folks are blowing this disclosure stuff out of proportion. IMO the company must keep some things to itself ,for certain periods, for the betterment of all. I bet there is A LOT we dont have a clue about, but I also feel we are in good hands. All IMO.
Lastly. Take a giant stop back 1 year, 2 years, etc. Are we in a better position now or a worse position. Look at all the facts.
All discaimers always apply to all my notes. |
